Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Investigators Highlight Promising T-Cell Response

 
• By Andrew McConaghie
  
Old Road Campus
Oxford is racing ahead in its Phase III trials, having dosed nearly all its target of 10,000 volunteers.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip